Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 17/20 | 0.83 |
| ▸ | CCKAR | P32238 | 2/20 | 0.72 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30816027 | 1.00 | CCKBR (0.83) | CCKBRCCKARIL23R | |
| SCHEMBL29408672 | 1.00 | CCKBR (0.83) | CCKBRCCKARIL23R | |
| SCHEMBL31236196 | 1.00 | CCKBR (0.83) | CCKBRCCKARIL23R | |
| SCHEMBL29408680 | 0.99 | CCKBR (0.82) | CCKBRCCKAR | |
| SCHEMBL31015828 | 0.98 | CCKBR (0.82) | CCKBRCCKARIL23R | |
| SCHEMBL31378333 | 0.98 | CCKBR (0.82) | CCKBRCCKARIL23R | |
| SCHEMBL30305897 | 0.98 | CCKBR (0.83) | CCKBRCCKARIL23R | |
| SCHEMBL31015850 | 0.98 | CCKBR (0.83) | CCKBRCCKARIL23R | |
| SCHEMBL31003974 | 0.96 | CCKBR (0.80) | CCKBRCCKARIL23R | |
| SCHEMBL29362904 | 0.96 | CCKBR (0.80) | CCKBRCCKARIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3429599-B1 | NANOPARTICLE TO TARGET CANCER | UNIV GEORGETOWN (US) | 2024-02-07 | — | — | EP | claimed |
| US-20240252696-A1 | TARGETING THE CHOLECYSTOKININ-B RECEPTOR FOR IMAGING AND EARLY DETECTION OF PANCREATIC CANCER AND PRE-CANCEROUS LESIONS | GEORGETOWN UNIVERSITY (US) | 2024-08-01 | — | — | US | disclosed |
| EP-3429599-B1 | NANOPARTICLE TO TARGET CANCER | UNIV GEORGETOWN (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230407265-A1 | COMPOSITION AND METHODS FOR 3D CULTURE OF ISLET CELLS | KANDEEL, FOUAD | 2023-12-21 | — | — | US | disclosed |
| US-11696922-B2 | Nanoparticle to target cancer | GEORGETOWN UNIVERSITY (US) | 2023-07-11 | — | — | US | disclosed |
| US-20220211738-A1 | NANOPARTICLE TO TARGET CANCER | GEORGETOWN UNIVERSITY (US) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220211738-A1 | NANOPARTICLE TO TARGET CANCER | CCKBR, CCKAR, LNPEP | CCKBR 1/4885CCKAR 2/4885IL23R 1079/4885 |
| US-20240252696-A1 | TARGETING THE CHOLECYSTOKININ-B RECEPTOR FOR IMAGING AND EARLY DETECTION OF PANCREATIC CANCER AND PRE-CANCEROUS LESIONS | CCKBR, CCKAR, PROKR1 | CCKBR 1/4885CCKAR 2/4885IL23R 416/4885 |
| US-11696922-B2 | Nanoparticle to target cancer | CCKBR, CCKAR, LNPEP | CCKBR 1/4885CCKAR 2/4885IL23R 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.